Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-6.74 Insider Own1.70% Shs Outstand42.86M Perf Week1.32%
Market Cap2.34B Forward P/E- EPS next Y-6.52 Insider Trans0.97% Shs Float39.26M Perf Month-1.29%
Income-277.40M PEG- EPS next Q-1.86 Inst Own- Short Float11.98% Perf Quarter-18.42%
Sales0.10M P/S23367.27 EPS this Y-56.90% Inst Trans-0.01% Short Ratio15.24 Perf Half Y-9.25%
Book/sh10.14 P/B5.38 EPS next Y8.70% ROA-52.90% Target Price68.75 Perf Year-11.45%
Cash/sh9.33 P/C5.85 EPS next 5Y30.40% ROE-60.00% 52W Range49.56 - 91.35 Perf YTD-22.46%
Dividend- P/FCF- EPS past 5Y- ROI-52.30% 52W High-40.31% Beta1.87
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low10.00% ATR1.87
Employees376 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)49.95 Volatility2.49% 3.50%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.00% Profit Margin- Rel Volume0.67 Prev Close53.95
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume308.64K Price54.52
Recom2.20 SMA200.99% SMA50-1.38% SMA200-15.77% Volume208,243 Change1.06%
Sep-14-17Upgrade Wedbush Neutral → Outperform $62
Aug-23-17Downgrade SunTrust Buy → Hold $55
Aug-17-17Initiated Evercore ISI In-line $63
Aug-08-17Reiterated H.C. Wainwright Neutral $72 → $75
Apr-19-17Downgrade Wedbush Outperform → Neutral $80 → $75
Apr-19-17Downgrade H.C. Wainwright Buy → Neutral $88 → $72
Apr-06-17Downgrade Jefferies Buy → Hold
Mar-23-17Downgrade Piper Jaffray Overweight → Neutral
Nov-14-16Downgrade Citigroup Neutral → Sell
Jul-07-16Initiated Piper Jaffray Overweight $70
Jun-28-16Initiated BofA/Merrill Buy
May-10-16Reiterated Wedbush Outperform $99 → $92
Mar-08-16Initiated Robert W. Baird Outperform $85
Feb-19-16Initiated Leerink Partners Outperform $80
Feb-09-16Initiated H.C. Wainwright Buy $104
Jan-21-16Initiated Credit Suisse Outperform
Jan-12-16Upgrade Citigroup Sell → Neutral
Dec-22-15Initiated Canaccord Genuity Buy $126
Dec-01-15Initiated Stifel Buy $125
Oct-23-15Resumed Jefferies Buy $108
Oct-16-17 09:43AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Oct-13-17 12:09PM  How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs Investor's Business Daily
11:18AM  WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders PR Newswire
Oct-10-17 08:30AM  Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumabs Biologics License Application GlobeNewswire
Oct-04-17 08:27AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017 Capital Cube
Oct-03-17 02:35PM  After bidding war, North Bay drug maker snags gene therapy company for $151 million American City Business Journals
12:20PM  After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout American City Business Journals
09:58AM  Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers TheStreet.com
08:30AM  Ultragenyx to Acquire Dimension Therapeutics GlobeNewswire
Oct-02-17 02:25PM  RegenxBio declines to push forward on planned acquisition American City Business Journals +7.62%
08:30AM  REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics GlobeNewswire
08:02AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
08:00AM  Dimension Board Determines that Ultragenyxs Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a Superior Proposal GlobeNewswire
Sep-25-17 09:57AM  Gene Therapy: A Big Week for Many Names Barrons.com
Sep-19-17 08:00AM  Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a Superior Proposal GlobeNewswire
Sep-18-17 03:10PM  Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx GlobeNewswire
01:18PM  UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid MarketWatch
09:35AM  Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers TheStreet.com
08:35AM  Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash GlobeNewswire
Sep-15-17 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical ACCESSWIRE
Sep-12-17 10:31AM  Ultragenyx's Burosumab Positive in Phase II for XLH and TIO Zacks
Sep-11-17 03:00PM  Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR GlobeNewswire
10:09AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Sep-08-17 10:25AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Sep-06-17 08:30AM  Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
08:05AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Aug-31-17 08:30AM  Ultragenyx to Present at the Baird 2017 Global Healthcare Conference GlobeNewswire
Aug-25-17 10:23AM  Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate Zacks
Aug-24-17 08:30AM  Ultragenyx Announces Burosumab Data Presentations at ASBMR 2017 Annual Meeting GlobeNewswire
08:30AM  Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumabs Biologics License Application in the US GlobeNewswire
08:10AM  Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Aug-23-17 05:15PM  Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today Motley Fool -13.31%
04:31PM  Why Omnicom Group Inc. (OMC), Ultragenyx Pharmaceutical Inc (RARE) and Stryker Corporation (SYK) Are 3 of Todays Worst Stocks InvestorPlace
04:06PM  Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data Zacks
03:37PM  Why Ultragenyx Pharmaceutical Stock Is Sinking Today Motley Fool
11:22AM  Ultragenyx Discontinues Phase 3 GNE Myopathy Study Benzinga
10:30AM  Ultragenyx Stumbles Over Late-Stage Trial 24/7 Wall St.
07:56AM  Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Zacks
Aug-22-17 07:50PM  Ultragenyx Pharmaceutical's Ace-ER trial misses the mark, shares crash Investing.com
04:49PM  Ultragenyx shares drop as muscle-disease drug study fails MarketWatch
04:05PM  Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy GlobeNewswire
Aug-21-17 08:02AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Aug-16-17 10:08PM  Ultragenyx Pharmaceutical, Inc. Value Analysis (NASDAQ:RARE) : August 17, 2017 Capital Cube
Aug-12-17 07:00AM  Edited Transcript of RARE earnings conference call or presentation 27-Jul-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:02AM  IHS Markit Score Update: Drop in demand for ETFs holding Ultragenyx Pharmaceutical Inc is a negative sign for its shares Markit
Aug-03-17 09:49AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : August 3, 2017 Capital Cube
Jul-28-17 08:05PM  Ultragenyx reports 2Q loss Associated Press
Jul-27-17 04:05PM  Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update GlobeNewswire
Jun-26-17 02:52PM  Seattle Genetics: A Disappointing StudyOr Was It? Barrons.com
Jun-23-17 08:30AM  Ultragenyx Provides Regulatory Update on Burosumab (KRN23) GlobeNewswire
Jun-21-17 04:38PM  Oh, baby: How expanded newborn screening could change the face of health care American City Business Journals
Jun-16-17 05:01PM  Ultragenyx Pharmaceutical, Inc. Value Analysis (NASDAQ:RARE) : June 16, 2017 Capital Cube
Jun-15-17 08:12AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : June 15, 2017 Capital Cube
Jun-09-17 01:19PM  Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct TheStreet.com
Jun-07-17 08:30AM  Ultragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
Jun-01-17 08:30AM  Ultragenyx to Present at Jefferies Global Healthcare Conference GlobeNewswire +5.13%
May-24-17 09:17AM  Ultragenyx Receives Priority Review for rhGUS from FDA Zacks
May-23-17 08:30AM  Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status GlobeNewswire
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. Business Wire
May-10-17 07:40PM  Edited Transcript of RARE earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents
08:30AM  Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference GlobeNewswire
May-05-17 05:03AM  Ultragenyx reports 1Q loss Associated Press
May-04-17 04:05PM  Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update GlobeNewswire
May-02-17 06:40PM  What's in Store for Catalyst (CPRX) Stock in Q1 Earnings? Zacks
Apr-28-17 04:05PM  Ultragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update GlobeNewswire
Apr-27-17 08:30AM  Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders GlobeNewswire
Apr-26-17 10:30AM  What's in Store for Nivalis (NVLS) this Earnings Season? Zacks
Apr-20-17 11:02AM  Company News for April 20, 2017 Zacks
Apr-19-17 04:45PM  Energy, biotech, financials & more in the trader blitz CNBC Videos
12:14PM  Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data Benzinga
10:38AM  Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III Zacks
10:30AM  Why Ultragenyx Pharmaceutical Stock Is Spiking Today Motley Fool
09:52AM  The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data Benzinga
09:50AM  Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data TheStreet.com
Apr-18-17 05:37PM  Ultragenyx surges on positive results for hypophosphatemia drug test MarketWatch
05:23PM  After-hours buzz: IBM, LRCX, RARE & more CNBC
04:01PM  Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-linked Hypophosphatemia PR Newswire
04:01PM  Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia GlobeNewswire
Apr-10-17 09:34AM  Ultragenyx's (RARE) XLH Drug Positive in Phase II Study Zacks
08:30AM  Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors GlobeNewswire
Apr-06-17 08:30AM  Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia GlobeNewswire -5.06%
08:30AM  Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia PR Newswire
Mar-24-17 08:15AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017 Capital Cube
Mar-23-17 03:34PM  Is It Time To Buy Ultragenxy? Barrons.com -8.13%
09:36AM  Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study Zacks
09:36AM  Biotech Premarket Movers: Insys, Ultragenyx, Alexion TheStreet.com
08:43AM  Ultragenyxs Seizure Drug Fails Study Investopedia
Mar-22-17 05:15PM  Ultragenyx falls on results of seizure medication study MarketWatch
05:04PM  Ultragenyx seizure drug fails mid-stage study Reuters
04:24PM  Ultragenyx seizure drug fails mid-stage study
04:05PM  Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study GlobeNewswire
Mar-02-17 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Feb-22-17 01:04PM  ULTRAGENYX PHARMACEUTICAL INC. Financials
Feb-21-17 11:56AM  Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical
Feb-17-17 06:06AM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report
12:01AM  Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT
Feb-16-17 04:42PM  Ultragenyx reports 4Q loss
04:10PM  ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update GlobeNewswire
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Children's Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAKKIS EMIL DPresident & CEOAug 28Buy52.527,500393,9222,559,741Aug 29 04:30 PM
Huizenga Theodore AlanVP, Controller and PAOMay 26Sale57.4648027,5819,366May 26 06:34 PM
Huizenga Theodore AlanController and PAOMar 09Sale86.342,500215,8459,709Mar 10 05:04 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 02Option Exercise0.8212,0009,78067,887Mar 03 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 02Sale90.1012,0001,081,17655,887Mar 03 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentDec 23Option Exercise0.816,5005,26551,887Dec 23 04:14 PM
Aliski WilliamDirectorDec 05Option Exercise21.006,000126,00065,985Dec 05 05:39 PM
Aliski WilliamDirectorDec 05Sale78.196,000469,16059,985Dec 05 05:39 PM
Huizenga Theodore AlanController and PAONov 16Option Exercise21.002,00042,00013,134Nov 18 04:11 PM
Huizenga Theodore AlanController and PAONov 16Sale79.732,000159,46011,134Nov 18 04:11 PM
KAKKIS EMIL DPresident & CEONov 15Sale81.2920,0001,625,753447,147Nov 17 04:01 PM
Sharp ShaliniCFO & Executive Vice PresidentNov 09Option Exercise0.8224,00019,56069,387Nov 10 11:18 AM
Sharp ShaliniCFO & Executive Vice PresidentNov 09Sale71.2024,0001,708,89445,387Nov 10 11:18 AM
Sharp ShaliniCFO & Senior Vice PresidentOct 19Option Exercise0.8212,0009,78057,387Oct 21 04:00 PM
Sharp ShaliniCFO & Senior Vice PresidentOct 19Sale61.4012,000736,82045,387Oct 21 04:00 PM